Company intelligence / Profile preview

DAVA Pharmaceuticals

Malvern / New Jersey*, Pennsylvania / New Jersey*, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Prior to its acquisition by Endo International plc in 2014, DAVA Pharmaceuticals operated a highly profitable generics franchise with $131 million revenue in 2013. The company developed and marketed a broad portfolio of generic pharmaceutical products across various therapeutic areas. No recent clinical results are available post-acquisition.

Modalities: Small molecules (primarily generics)
Industry: Biotech

Drug pipeline

2 assets

doxycycline

Commercial

Indications: Bacterial infections

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on DAVA Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAVA Pharmaceuticals.

Explore the full profile